NCT04435041 is a clinical trial in COVID-19, sponsored by University of Oxford.

Who is sponsoring NCT04435041?

NCT04435041 is sponsored by University of Oxford.

Is NCT04435041 still recruiting?

NCT04435041 is currently completed. Last updated 11 April 2022.

Last reviewed 2022-04-11 · How we verify

NCT04435041

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Remote-by-Default Care in the COVID-19 Pandemic

Completed Last updated 11 April 2022

What this trial tests

trial in COVID-19 in 103 participants. Completed in 28 February 2022.

Timeline

13 May 2020

Primary endpoint
27 July 2021

28 February 2022

Quick facts

Lead sponsor	University of Oxford
Status	Completed
Study type	OBSERVATIONAL
Enrollment	103
Start date	13 May 2020
Primary completion	27 July 2021
Estimated completion	28 February 2022
Sites	1 location across United Kingdom

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

University of Oxford

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

18 month study, funded by ESRC COVID-19 research fund. The aim is to explore and support the rapid shift from face-to-face to remote (telephone and video) conversations in primary care. There are three components: a study of clinical interactions and decision making (micro); four locality-based organisational case studies of new models of care (meso); abd a a study of how digital innovation can support NHS infrastructure and vice versa (macro).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services.
Ladds E, Rushforth A, Wieringa S, Taylor S, et al · · 2020 · cited 407× · PMID 33342437 · DOI 10.1186/s12913-020-06001-y
Why do GPs rarely do video consultations? qualitative study in UK general practice.
Greenhalgh T, Ladds E, Hughes G, Moore L, et al · · 2022 · cited 78× · PMID 35256385 · DOI 10.3399/bjgp.2021.0658
What items should be included in an early warning score for remote assessment of suspected COVID-19? qualitative and Delphi study.
Greenhalgh T, Thompson P, Weiringa S, Neves AL, et al · · 2020 · cited 36× · PMID 33184088 · DOI 10.1136/bmjopen-2020-042626
Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality criteria for services
Ladds E, Rushforth A, Wieringa S, Taylor S, et al · · 2020 · cited 5× · DOI 10.1101/2020.10.13.20211854
An Early Warning Risk Prediction Tool (RECAP-V1) for Patients Diagnosed With COVID-19: Protocol for a Statistical Analysis Plan.
Fiorentino F, Prociuk D, Espinosa Gonzalez AB, Neves AL, et al · · 2021 · cited 3× · PMID 34468322 · DOI 10.2196/30083

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04435041 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 11 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04435041.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing